Concededly, pity is not a word often linked with people’s perceptions of business actors operating within the health care industry. Entities like large hospital chains, pharmaceutical companies, device makers and insurers are often viewed as too-big-to-fail entities that amass incalculably high profits and are beyond the reach of any real injury inflicted by outside forces….
Stories in New York and across the country seem to surface just about every day to underscore — as we note on our health care law website at Daniels, Porco & Lusardi, LLP — that, “Within the health care arena, every legal matter comes with layers of regulatory and compliance issues that must be addressed.”…
As we have duly noted in prior select posts, many individuals and enterprises operating within the health care realm in New York and nationally are routinely under intense public and regulatory scrutiny. And among all those industry participants, there is perhaps no other entity so closely perused as the U.S. Food and Drug Administration, especially…
Doctor-owned medical facilities — chiefly hospitals — are bad for consumers and the public health. No, wait a minute, they’re a positive development that materially promotes a salutary bottom line in a truly broad-based way. Those polar-opposite views are the core bullet points in any debate focusing upon close physician involvement in an ownership capacity…
Health care facilities should be concerned about regulatory compliance matters for the sake of their future business operations. If violations are found, a facility might lose its accreditation and/or right to lawfully operate. Yet according to a recent article, passing an inspection from a private health care accreditor may not necessarily put a facility in…
A doctor who makes it a point to speak to medical student groups and at health-care forums says that she always seeks to underscore for her audience that, “Wow, this is how it happens.” It happens like this for doctors with growing medical practices. Diverse groups of people — termed a “parade of drug, device…
Recent New York-based news relevant to the health care industry bears special significance for one emerging class of participants in that realm, on at least two material fronts. First, a recent money settlement clearly indicates a newly heightened regulatory focus on so-called “digital health companies,” which most consumers might more familiarly know as online health…
Opportunities, yes. And challenges across all dimensions, too, with related management and liability concerns — a reality that is simply a commonplace for American medical actors across all spheres. Any individual in New York or elsewhere who is even remotely connected with the medical industry in any capacity flatly knows the unrelenting bureaucratic and regulatory…
In the realm of federal oversight over marketplace drug approval, do officials from the U.S. Food and Drug Administration act so cautiously that they dangerously slow up the process and materially delay the marketplace entrance of new drugs and medications that many consumers badly need? Or, conversely, do they signal approval in precipitous fashion, so…
One commentator in a recent national media focus on medical actors being targeted in criminal and civil investigations refers to “a new permutation” that is well worth noting in the health care industry. He calls it “the beginning of the next round” for what might be in store for legions of medical industry participants, ranging…